|Mr. Michael A. Mussallem||Chairman & CEO||3.38M||48.81M||1953|
|Mr. Scott B. Ullem||Corp. VP & CFO||1.32M||N/A||1967|
|Mr. Donald E. Bobo Jr.||Corp. VP of Strategy & Corp. Devel.||1.27M||4.56M||1962|
|Mr. Larry L. Wood||Corp. VP of Transcatheter Heart Valve||1.36M||5.46M||1966|
|Ms. Catherine M. Szyman||Corp. VP of Critical Care||1.36M||N/A||1967|
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation’s ISS Governance QualityScore as of October 1, 2018 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 2; Compensation: 3.